Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.
about
Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development.Physiologically Based Pharmacokinetic Modelling of Cytochrome P450 2C9-Related Tolbutamide Drug Interactions with Sulfaphenazole and Tasisulam.Allometry Is a Reasonable Choice in Pediatric Drug Development.Can Population Modelling Principles be Used to Identify Key PBPK Parameters for Paediatric Clearance Predictions? An Innovative Application of Optimal Design Theory
P2860
Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Optimizing pharmacokinetic bri ...... ing: application to docetaxel.
@ast
Optimizing pharmacokinetic bri ...... ing: application to docetaxel.
@en
type
label
Optimizing pharmacokinetic bri ...... ing: application to docetaxel.
@ast
Optimizing pharmacokinetic bri ...... ing: application to docetaxel.
@en
prefLabel
Optimizing pharmacokinetic bri ...... ing: application to docetaxel.
@ast
Optimizing pharmacokinetic bri ...... ing: application to docetaxel.
@en
P2093
P2860
P356
P1476
Optimizing pharmacokinetic bri ...... ing: application to docetaxel.
@en
P2093
Christine Veyrat-Follet
Florent Mazuir
Hoai-Thu Thai
Sylvaine Cartot-Cotton
P2860
P304
P356
10.1111/BCP.12702
P407
P577
2015-06-19T00:00:00Z